Eli Lilly and Company (LLY)
$1197.13+6.16%
Spriggl Score: Good— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“GLP-1 franchise leader; Q1 beat and raised guidance are positives, but 56% concentration and premium valuation cap conviction.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, H…
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - General
- Market Cap:
- $979.6B
Recent dividends
- 14 Aug 2026$1.73
- 15 May 2026$1.73
- 13 Feb 2026$1.73
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Eli Lilly and Company and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free